<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038813</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-E-003</org_study_id>
    <nct_id>NCT05038813</nct_id>
  </id_info>
  <brief_title>Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)</brief_title>
  <official_title>A Single-arm, Multi-center Exploratory Clinical Study of Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor)&#xD;
      in the first-line treatment of patients with advanced ESCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>about 2 years</time_frame>
    <description>The RECIST1.1 and iRECIST standards were used to evaluate the efficacy of drugs, with the RECIST1.1 evaluation standard as the main and the iRECIST standard as a supplement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety:adverse events</measure>
    <time_frame>about 2 years</time_frame>
    <description>adverse events (AEs) categorized by severity in accordance with the NCI CTC AE Version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>about 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>about 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DoR)</measure>
    <time_frame>about 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>about 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib combined with TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib+TQB2450</intervention_name>
    <description>Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.&#xD;
TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months.</description>
    <arm_group_label>Anlotinib combined with TQB2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient voluntarily joined the study, signed an informed consent form, had good&#xD;
             compliance, and cooperated with the follow-up.&#xD;
&#xD;
          -  Unresectable locally advanced, unresectable recurrent or metastatic ESCC confirmed by&#xD;
             histopathology (excluding mixed adenosquamous carcinoma);&#xD;
&#xD;
          -  Patients who have not received systemic treatment in the past, or who have previously&#xD;
             received (neo) adjuvant treatment/radical treatment programs (including radical&#xD;
             surgical resection and radical radiotherapy and chemotherapy programs) who have&#xD;
             relapsed for more than 6 months; Note: Including patients with advanced or recurring&#xD;
             non-target lesions who have progressed again after simple radiotherapy. For local&#xD;
             lesions (non-target lesions), the time from the end of palliative treatment to the&#xD;
             enrollment time is&gt; 2 weeks;&#xD;
&#xD;
          -  According to the RECIST version 1.1 of the curative effect evaluation standard for&#xD;
             solid tumors, there is at least one measurable lesion, and it can be accurately&#xD;
             measured by magnetic resonance imaging (MRI) or computed tomography (CT) in at least&#xD;
             one direction (the largest diameter needs to be recorded) , Where the longest diameter&#xD;
             at baseline is ≥10 mm (if it is a lymph node, the short diameter is required to be ≥15&#xD;
             mm); the measurable lesions should not have received local treatment such as&#xD;
             radiotherapy (the lesions located in the previous radiotherapy area, if it is&#xD;
             confirmed to have progressed, and meet RECIST1.1 standard, target lesions can also be&#xD;
             selected);&#xD;
&#xD;
          -  Male or female patients between 18-75 years old;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) physical status (PS) score: 0-1 points;&#xD;
&#xD;
          -  The estimated survival period exceeds 3 months;&#xD;
&#xD;
          -  Possess sufficient organ and bone marrow function, that is, meet the following&#xD;
             standards:&#xD;
&#xD;
               1. Routine blood examination standards must be met (no blood transfusion and blood&#xD;
                  products within 14 days, no correction with G-CSF and other hematopoietic&#xD;
                  stimulating factors):Hemoglobin content (HB) ≥100g/L; White blood cell content&#xD;
                  (WBC) ≥3.0×10^9/L; Neutrophil count (ANC)≥1.5×10^9/L; Platelet count (PLT)&#xD;
                  ≥75×10^9/L.&#xD;
&#xD;
               2. The biochemical inspection shall meet the following standards:Total serum&#xD;
                  bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); ALT and AST≤2.5ULN;&#xD;
                  if there is liver metastasis, ALT and AST≤5ULN;Cr≤1.5ULN or creatinine clearance&#xD;
                  rate (CCr)≥60ml/min, (Cockcroft-Gault formula).&#xD;
&#xD;
               3. Adequate coagulation function, defined as International Normalized Ratio (INR) or&#xD;
                  Prothrombin Time (PT) ≤ 1.5 times ULN;&#xD;
&#xD;
               4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ lower&#xD;
                  limit of normal value (50%);&#xD;
&#xD;
               5. Myocardial enzyme spectrum: within the normal range.&#xD;
&#xD;
          -  Women of childbearing age must take appropriate contraceptive measures from screening&#xD;
             to 3 months after stopping the study treatment, and participants must be non-lactating&#xD;
             patients. Before starting the administration, the pregnancy test is negative, or&#xD;
             meeting one of the following criteria proves that there is no risk of pregnancy:&#xD;
&#xD;
               1. Postmenopausal is defined as amenorrhea at least 12 months after the age is over&#xD;
                  50 years and all exogenous hormone replacement therapy is stopped;&#xD;
&#xD;
               2. For women younger than 50 years old, if the amenorrhea is 12 months or more after&#xD;
                  stopping all exogenous hormone treatments, and the luteinizing hormone (LH) and&#xD;
                  follicle stimulating hormone (FSH) levels are within the laboratory&#xD;
                  postmenopausal reference value range, also Can be considered post-menopausal;&#xD;
&#xD;
               3. Have received irreversible sterilization, including hysterectomy, bilateral&#xD;
                  ovariectomy or bilateral fallopian tube resection, except for bilateral tubal&#xD;
                  ligation.&#xD;
&#xD;
          -  For men, participants must agree to use appropriate methods of contraception or have&#xD;
             been surgically sterilized during the trial period and 8 weeks after the last trial&#xD;
             drug administration;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received Anlotinib hydrochloride treatment or any&#xD;
             anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibody treatment;&#xD;
&#xD;
          -  It is known that ESCC tends to be completely obstructed under endoscopy and requires&#xD;
             interventional therapy to relieve the obstruction;&#xD;
&#xD;
          -  ESCC patients with ulcer; Note: This mainly refers to patients whose ulcers are&#xD;
             adjacent to blood vessels which increase the risk of bleeding.&#xD;
&#xD;
          -  Patients who have received stent implantation in the esophagus or trachea;&#xD;
&#xD;
          -  Patients who have a higher risk of bleeding or perforation due to the tumor's obvious&#xD;
             invasion of the adjacent organs (aorta or trachea) of the esophageal lesion, or&#xD;
             patients who have formed a fistula;&#xD;
&#xD;
          -  Received major surgical treatment, open biopsy or obvious traumatic injury within 28&#xD;
             days before enrollment;&#xD;
&#xD;
          -  There are a variety of factors that affect the use of therapeutic drugs, such as:&#xD;
             inability to swallow or chronic diarrhea or intestinal obstruction, significantly&#xD;
             affecting the administration and absorption of the drug, or a known history of severe&#xD;
             allergies to any of the drug components in this study.&#xD;
&#xD;
          -  The patient has received anti-tumor treatment with Chinese medicine in the past 2&#xD;
             weeks (Chinese medicine contains the following medicinal materials such as Brucea&#xD;
             javanica, coix seed, lentinan, cantharidin, toad skin, astragalus, sophora flavescens,&#xD;
             black bone vine, myrobalan, etc.), However, patients who took more than 2 weeks from&#xD;
             the last anti-tumor treatment of Chinese medicine are allowed to join the group;&#xD;
&#xD;
          -  The burden of liver metastases accounts for more than 50% of the entire liver volume;&#xD;
&#xD;
          -  Patients with any severe and/uncontrolled diseases, including:&#xD;
&#xD;
               1. Patients with poor blood pressure control using antihypertensive drugs (systolic&#xD;
                  blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); or patients&#xD;
                  using two or more antihypertensive drugs to control blood pressure; previous&#xD;
                  hypertensive crisis or high Patients with blood pressure encephalopathy;&#xD;
&#xD;
               2. Patients with grade I or higher myocardial ischemia or myocardial infarction,&#xD;
                  arrhythmia (including QTc interval &gt;450ms for men and &gt;470ms for women) and&#xD;
                  congestive heart failure ≥2 (New York Heart Association (NYHA) classification),&#xD;
                  severe /Unstable angina) and patients who have undergone coronary/peripheral&#xD;
                  artery bypass surgery;&#xD;
&#xD;
               3. Active or uncontrolled serious infection (≥CTCAE grade 2 infection), and those&#xD;
                  who are known to have active tuberculosis;&#xD;
&#xD;
               4. Renal failure requires hemodialysis or peritoneal dialysis&#xD;
&#xD;
               5. Liver diseases such as liver cirrhosis, decompensated liver disease, chronic&#xD;
                  active hepatitis;&#xD;
&#xD;
               6. Poor control of diabetes (fasting blood glucose (FBG)&gt;10mmol/L);&#xD;
&#xD;
               7. Urine routine test shows that urine protein is ≥++, and the 24-hour urine protein&#xD;
                  quantification is confirmed to be &gt;1.0 g;&#xD;
&#xD;
          -  Long-term unhealed wounds or fractures;&#xD;
&#xD;
          -  Patients with symptoms of hematemesis, hematochezia and daily bleeding ≥2.5mL, or any&#xD;
             bleeding event ≥CTCAE level 3 within 3 months before screening, or any bleeding signs&#xD;
             or medical history judged by the investigator to be unsuitable regardless of the&#xD;
             severity Enrolled patients; or patients with abnormal coagulation function (INR&gt;1.5 or&#xD;
             prothrombin time (PT)&gt;ULN+4 seconds or APTT&gt;1.5 ULN), have bleeding tendency or are&#xD;
             receiving thrombolytic or anticoagulant therapy; Note: Under the premise that the&#xD;
             international normalized ratio of prothrombin time (INR) ≤ 1.5, the use of low-dose&#xD;
             heparin (daily dosage for adults is 6,000 to 12,000 U) or low-dose aspirin (daily&#xD;
             dosage ≤ 100 mg);&#xD;
&#xD;
          -  A history of gastrointestinal perforation and/or fistula in the 6 months before the&#xD;
             enrollment treatment; or arterial/venous thrombotic events, such as cerebrovascular&#xD;
             accidents (including temporary ischemic attacks), deep vein thrombosis and lungs&#xD;
             Embolizer&#xD;
&#xD;
          -  Central nervous system metastases and/or cancerous meningitis with symptoms or active&#xD;
             stages are known to exist;&#xD;
&#xD;
          -  Ascites with clinical significance, including any ascites that can be found on&#xD;
             physical examination, ascites that has been treated in the past or that still needs to&#xD;
             be treated, and only those with a small amount of ascites but asymptomatic on imaging&#xD;
             can be selected;&#xD;
&#xD;
          -  Patients with moderate effusion in both pleural cavities, or large effusion in one&#xD;
             pleural cavity, or patients who have caused respiratory dysfunction and need drainage;&#xD;
&#xD;
          -  Suffer from interstitial lung disease that requires steroid therapy;&#xD;
&#xD;
          -  Uncontrolled metabolic disorders or secondary reactions of other non-malignant tumor&#xD;
             organs or systemic diseases or cancers, which may lead to higher medical risks and/or&#xD;
             uncertainty in survival evaluation;&#xD;
&#xD;
          -  Those who have a history of psychotropic drug abuse and cannot be quit or have mental&#xD;
             disorders;&#xD;
&#xD;
          -  Have a history of immunodeficiency, including those who have tested positive for HIV&#xD;
             or have other acquired or congenital immunodeficiency diseases, or have a history of&#xD;
             organ transplantation;&#xD;
&#xD;
          -  History of other primary malignant tumors, except for the following: a) Malignant&#xD;
             tumors that have been completely remitted for at least 2 years before enrollment and&#xD;
             no other treatment is required during the study period; b) Non-melanoma skin that has&#xD;
             been adequately treated and has no evidence of disease recurrence Carcinoma or&#xD;
             malignant freckle-like nevus; c) Carcinoma in situ that has been adequately treated&#xD;
             and has no evidence of disease recurrence;&#xD;
&#xD;
          -  Any of the following immune-related medical history and treatment history:&#xD;
&#xD;
               1. There is any active autoimmune disease or a history of autoimmune disease (the&#xD;
                  following but not limited to: autoimmune hepatitis, interstitial pneumonia,&#xD;
                  enteritis, vasculitis, nephritis; subjects who require bronchodilators for&#xD;
                  medical intervention Asthma cannot be included); but the following patients are&#xD;
                  allowed to be included in the group: vitiligo, psoriasis, hair loss without&#xD;
                  systemic treatment, well-controlled type I diabetes, and hypothyroidism with&#xD;
                  normal thyroid function after replacement therapy;&#xD;
&#xD;
               2. Diagnosed with immunodeficiency or are receiving systemic glucocorticoid therapy&#xD;
                  or any other form of immunosuppressive therapy (dose&gt;10mg/day of prednisone or&#xD;
                  other curative hormones), and remain within 2 weeks before the first&#xD;
                  administration Continuing to use&#xD;
&#xD;
               3. Have received any live vaccines, attenuated vaccines (including anti-infective&#xD;
                  vaccines, such as flu vaccines, varicella vaccines, etc.) or inactivated vaccines&#xD;
                  within 4 weeks before enrollment, and plan to vaccinate live vaccines/attenuated&#xD;
                  vaccines/inactivated vaccines during the study period Vaccine; used systemic&#xD;
                  immunostimulatory agents (including but not limited to interferon and IL-2)&#xD;
                  within 2 weeks before the start of the study treatment;&#xD;
&#xD;
          -  During pregnancy or lactation, or planning to become pregnant during the study period&#xD;
             or within 3 months after the last administration of TQB2450 or Anlotinib;&#xD;
&#xD;
          -  According to the judgment of the investigator, there is a concomitant disease that&#xD;
             seriously endangers the safety of the patient or affects the patient to complete the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Feng Wang, doctor</last_name>
    <phone>0086-13938244776</phone>
    <email>fengw010@163.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Feng Wang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

